Assessment of Citramel in Patients with Cystic Fibrosis
A Double-blind Randomised Placebo-controlled Cross-Over Study of the Effects of Citramel on the Signs and Symptoms of Cystic Fibrosis
Breathe Easy Ltd
24 participants
Jun 7, 2016
Interventional
Conditions
Summary
This is a research study to evaluate Citramel inhalation. It is a double-blind, placebo, cross-over design to assess the safety, tolerability and efficacy of Citramel in approx. 24 cystic fibrosis patients.
Eligibility
Inclusion Criteria1
- Confirmed diagnosis of cystic fibrosis; aged at least 16 years who provide written informed consent; sexually active females must use contraception; stable medications; FEV1 between 40-100% of normal range.
Exclusion Criteria1
- Clinically significant co-existing disease; current or previous clinically significant smoking history; ECG or blood pressure abnormalities; use of a bronchodilator within 12hrs prior to bronchodilator challenge at screening; renal impairment; elevated liver enzymes;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Citramel - an aqueous solution of sodium citrate (16.18 mg/mL), citric acid (0.046 mg/mL) and ammonium chloride (4.12 mg/mL). Administered by aerosol twice daily (morning and night) for 28 days. This study is a randomised crossover design and there is a washout period of 14 days before the second study treatment is started. For patients being treated with Tobramycin: this should be administered at least ten minutes after completion of the inhalation of study medication is inhaled. Note that the nebulizing equipment provided for the study medications should NOT be used to administer tobramycin.
Locations(4)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000654550